Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Melichar, Bohuslav ^a   Hyšpler, Radomír ^a   Dragounová, Emanuela ^a   Dvořák, Josef ^a   Kalábová, Hana ^a   Tichá, Alena ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; LACTULOSE; MANNITOL; PACLITAXEL; SUCROSE; TRASTUZUMAB; XYLOSE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CAPILLARY GAS CHROMATOGRAPHY; CARBOHYDRATE ABSORPTION; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LEUKOPENIA; LOADING DRUG DOSE; NAUSEA; NEUTROPENIA; OVARY CANCER; PROVOCATION TEST; RANK SUM TEST; REFERENCE VALUE; STOMATITIS; URINALYSIS; WILCOXON SIGNED RANKS TEST; ADENOCARCINOMA; BREAST TUMOR; CELL MEMBRANE PERMEABILITY; DRUG EFFECT; GASTROINTESTINAL TRACT; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CELL MEMBRANE PERMEABILITY; CISPLATIN; FEMALE; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; LACTULOSE; MANNITOL; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; SUCROSE; XYLOSE;

EID: 34548590421     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-155     Document Type: Article

References (26)

1. McGuire WP Hoskins WJ Brady MF Kucera PR Partridge EE Look KY Clarke-Pearson DL Davidson M Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 1996, 334:1-6. 10.1056/NEJM199601043340101 7494563
2. Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye S Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumulo S Timmers P Roy JA Lhoas F Lindvall B Bacon M Birt A Andersen JE Zee B Paul J Baron B Pecorelli S Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results J Natl Cancer Inst 2000, 92:699-708. 10.1093/ jnci/92.9.699 10793106
3. Fountzilas G Kalofonos HP Dafni U Papadimitriou C Bafaloukos D Papakostas P Kalogera-Fountzila A Gogas H Aravantinos G Moulopoulos LA Economopoulos T Pectasides D Maniadakis N Siafaka V Briasoulis E Christodoulou C Tsavdaridis D Makrantonakis P Razis E Kosmidis P Skarlos D Dimopoulos MA Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group Ann Oncol 2004, 15:1517-1526. 10.1093/annonc/mdh395 15367413
4. Hainsworth JD Erland JB Kalman LA Schreeder MT Greco FA Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended schedule etoposide J Clin Oncol 1997, 15:2385-2393. 9196154
5. Rubenstein EB Peterson DE Schubert M Keefe D McGuire D Epstein J Elting LS Fox PC Cooksley C Sonis ST Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis Cancer 2004, 100:2026-2046. 10.1002/ cncr.20163 15108223
6. Sonis ST Etting LS Keefe D Peterson DE Schubert M Hauer-Jensen M Bekele DN Raber-Durlacher J Donnely JP Rubenstein EB Perspectives on cancer therapy-induced mucosal injury Cancer 2004, 100:1995-2025. 10.1002/ cncr.20162 15108222
7. Lorusso D Ferrandina G Graggi S Gadduci A Pignata S Tateo S Biamonte R Manzione L Di Vagno G Ferrau F Scambia G Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients Ann Oncol 2003, 14:1086-1093. 10.1093/annonc/mdg301 12853351
8. Bjarnason I Macpherson A Hollander D Intestinal permeability: An overview Gastroenterology 1995, 108:1566-1581. 10.1016/ 0016-5085(95)90708-4 7729650
9. Uil JJ van Elburg RM van Overbeek FM Mulder CJJ van Berge-Henegouwen GP Heymans HSA Clinical implications of the sugar absorption test: intestinal permeability test to assess mucosal barrier function Scand J Gastroenterol 1997, 32:70-78. 9018770
10. Meddings JB Sutherland LR Byles NI Wallace JL Sucrose: A novel permeability marker for gastroduodenal disease Gastroenterology 1993, 104:1619-1626. 8500718
11. Melichar B Dvorak J Hyspler R Zadak Z Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents Chemotherapy 2005, 51:336-338. 10.1159/000088957 16224185
12. Common Terminology Criteria for Adverse Events version 3.0 http://ctep.cancer.gov/reporting/ctc_v30.html
13. Melichar B Urbanek L Krcmova L Kalabova H Svobodova I Dragounova E Vesely P Hyspler R Solichova D Urinary neopterin in patients with ovarian cancer Pteridines 2006, 17:145-153.
14. Matthews JNS Altman DG Campbel MJ Royston P Analysis of serial measurements in medical research Br Med J 1990, 300:230-235.
15. Parrilli G Iaffaioli RV Capuano G Budillon G Bianco AR Changes in intestinal permeability to lactulose by cytotoxic chemotherapy Cancer Treat Rep 1982, 66:1435-1436. 7083246
16. Parrilli G Iaffaioli RV Martorano M Cuomo R Tafuto S Zampino MG Budillon G Bianco AR Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancer Cancer Res 1989, 49:3689-3691. 2731182
17. Kohout P Cerman J Bratova M Zadak Z Small bowel permeability in patients with cytostatic therapy Nutrition 1999, 15:546-549. 10.1016/ S0899-9007(99)00113-6 10422084
18. Daniele B Secondulfo M De Vivo R Pignata S De Magistris L Delrio P Palaia R Barletta E Tambaro R Carratu R Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer J Clin Gastroenterol 2001, 32:228-230. 10.1097/00004836-200103000-00010 11246350
19. Fazeny-Dörner B Vetl M Wenzel C Brodowicz T Zielinski C Muhm M Vogelsang H Marosi C Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine) Cancer Chemother Pharmacol 2002, 49:294-298. 10.1007/ s00280-001-0414-2 11914908
20. Gonzalez-Martin AJ Calvo E Bover I Rubio MJ Arcusa A Casado A Ojeda B Balana C Martínez E Herrero A Pardo B Adrover E Rifa J Godes MJ Moyano A Cervantes A Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study Ann Oncol 2005, 16:749-755l. 10.1093/annonc/mdi147 15817604
21. Havrilesky LJ Alvarez AA Sayer RA Lancaster JM Soper JT Berchuck A Clarke-Pearson DL Rodriguez GC Carney ME Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer Gyn Oncol 2003, 88:51-57. 10.1006/gyno.2002.6859
22. Vasey PA Gordon CJ Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A Kaye SB Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma J Natl Cancer Inst 2004, 96:1682-1691. 15547181
23. Melichar B Kohout P Bratova M Solichova D Kralickova P Zadak Z Intestinal permeability in patients with chemotherapy-induced stomatitis J Cancer Res Clin Oncol 2001, 127:314-318. 10.1007/s004320000209 11355146
24. Bow EJ Loewen R Cheang MS Shore TB Rubinger M Schacter B Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults J Clin Oncol 1997, 15:2254-2261. 9196138
25. Blijlevens NMA van t Land B Donnely JP Rabet L De Pauw BF Measuring mucosal damage induced by cytotoxic therapy Support Care Cancer 2004, 12:227-233. 10.1007/s00520-003-0572-3 14752625
26. DeMeo MT Mutlu EA Keshavarzian A Tobin MC Intestinal permeation and gastrointestinal disease J Clin Gastroenterol 2002, 34:385-396. 10.1097/ 00004836-200204000-00003 11907349